Gaucher Disease
Links shared publicly online about this topic
Gaucher disease: FDA approves VPRIV
news-medical.net — “The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.” View full resource at news-medical.net
Most Recently Shared on February 27, 2010 at 4:57 am By:
Stroke News: Gaucher disease: FDA approves VPRIV: The U.S. Food and Drug Administration has approved velaglucera... http://twurl.nl/zaidct
FDA Approves VPRIV to Treat Gaucher Disease
drugs.com — “VPRIV (velaglucerase alfa) is used to treat Gaucher disease. Includes VPRIV side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on February 28, 2010 at 5:02 am By:
FDA Approves VPRIV to Treat Gaucher Disease - http://bit.ly/dATgn7
Gastro Medical News about Gaucher Disease
mdlinx.com — “The US Food and Drug Administration Approves a New Gaucher Disease Drug” View full resource at mdlinx.com
Most Recently Shared on June 8, 2010 at 7:54 pm By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
The US Food and Drug Administration Approves a New Gaucher Disease Drug: Gastroenterology http://bit.ly/d1S9dg #GI
FDA Approves Therapy To Treat Gaucher Disease
tweetmeme.com — “The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease. Gaucher disease occurs in people who do not produce enough of an enzy” View full resource at tweetmeme.com
Most Recently Shared on February 27, 2010 at 2:49 pm By:
Healthcare TweetMeme Health Social Media
FDA Approves Therapy To Treat Gaucher Disease http://retwt.me/1MjGN (via @healthytweet)
Vpriv available for Type 1 Gaucher disease - ONA
oncologynurseadvisor.com — “Shire announced that Vpriv (velaglucerase alfa for injection) has been FDA approved and made available for the treatment of Type 1 Gaucher disease.” View full resource at oncologynurseadvisor.com
Most Recently Shared on March 1, 2010 at 4:13 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Vpriv available for Type 1 Gaucher disease http://goo.gl/fb/3kQb
Scientists shed light on potential treatment for Gaucher's disease
sciencedaily.com — “In findings that advance scientists' understanding of a whole class of inherited disorders, a research team has shed light on a mechanism that enables a potential treatment for Gaucher's disease and other lysosomal storage diseases.” View full resource at sciencedaily.com
Most Recently Shared on May 10, 2010 at 3:06 am By:
Scientists shed light on potential treatment for Gaucher's disease: In findings that advance scientists' understan... http://bit.ly/c75LfG
Phase II Study Of An Oral Therapy For Gaucher Disease Yields Positive Results
medicalnewstoday.com — “Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a” View full resource at medicalnewstoday.com
Most Recently Shared on May 5, 2010 at 12:18 pm By:
MNT Clinical Trials Health News
Phase II Study Of An Oral Therapy For Gaucher Disease Yields Positive Results http://mnt.to/3C85 #clinicaltrials
Cheaper, More Effective Treatment of Type 1 Gaucher Disease Possible
opa.yale.edu — “Cheaper, More Effective Treatment of Type 1 Gaucher Disease Possible” View full resource at opa.yale.edu
Most Recently Shared on October 20, 2010 at 4:21 pm By:
School of Medicine Medical School
New light on Type 1 Gaucher Disease: http://bit.ly/9KneM0
Oral therapy for Gaucher disease: Study yields positive results
sciencedaily.com — “Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a new study, researchers present positive results of a Phase II clinical trial of eliglustat tartrate, an oral therapy in development to treat Gaucher disease.” View full resource at sciencedaily.com
Most Recently Shared on May 3, 2010 at 9:30 pm By:
Oral therapy for Gaucher disease: Study yields positive results: Gaucher disease, a rare enzyme deficiency disorde... http://bit.ly/bEUKir
Phase II study of an oral therapy for Gaucher disease yields positive results
physorg.com — “Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a study published online today in Blood, the journal of the American Society of Hematology, researchers present positive results of a Phase II clinical trial of eliglustat ...” View full resource at physorg.com
Most Recently Shared on May 3, 2010 at 9:40 pm By:
PhysOrg Health News Health News
Phase II study of an oral therapy for Gaucher disease yields positive results http://tw.physorg.com/192124667
Cheaper, more effective treatment of type 1 Gaucher disease possible
labspaces.net — “Researchers at Yale School of Medicine have found that new disease pathways involving more than one cell type leads to Type 1 Gaucher disease, a rare genetic disorder in which fatty substances called glycosphingolipids accumulate in cells, resulting in liver/spleen enlargement, osteoporosis, bone pain, and increased risk of cancer and Parkinson's disease.” View full resource at labspaces.net
Most Recently Shared on October 20, 2010 at 5:20 pm By:
Cheaper, more effective treatment of type 1 Gaucher disease possible - http://is.gd/g9XvV
Shire receives approval for VPRIV to treat type 1 Gaucher disease
news-medical.net — “Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.” View full resource at news-medical.net
Most Recently Shared on August 27, 2010 at 10:15 am By:
Shire receives approval for VPRIV to treat type 1 Gaucher disease: Shire, the global specialty biopharmaceutical c... http://bit.ly/d0YvUf
Protalix shares plunge as FDA rejects Gaucher disease drug - Proactiveinvestors (NA)
proactiveinvestors.com — “Protalix BioTherapeutics' (AMEX:PLX) shares dove nearly 28% on Friday after the company announced the FDA did not approve its new drug being developed with Pfizer for the treatment of Gaucher, a genetic disease that causes fat to build up in the body.” View full resource at proactiveinvestors.com
Most Recently Shared on February 26, 2011 at 3:32 am By:
Sandeep Pulim Health Communicator, Physician, and Doctor
Protalix shares plunge as FDA rejects Gaucher disease drug - Proactiveinvestors (NA) http://t.co/x5gJmIp
Gaucher Disease - Physiopedia - The physiotherapy and physical therapy wiki and encyclopaedia
physio-pedia.com — “Written by physiotherapists and physical therapists for the physiotherapy and physical therapy profession, the aim is to create an international on-line resource for accessible for all rehabilitation and health care professionals.” View full resource at physio-pedia.com
Most Recently Shared on February 28, 2011 at 5:15 pm By:
Gaucher Disease http://goo.gl/fb/w4dhQ
Gene Behind Gaucher Disease a Player in Parkinson’s at Kerentech
kerentech.com — “'For those of us who work with rare disorders, it is heartwarming to come up with insights that are applicable to more common disorders,' said Dr. Ellen...” View full resource at kerentech.com
Most Recently Shared on October 22, 2009 at 3:19 pm By:
Dr Robert Schertzer Physician, Doctor, and Ophthalmologist
RT @EstherMoscatel Gene Behind Gaucher Disease a Player in Parkinson's http://is.gd/4vV1m
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
News-Medical.Net
Stay up to date with the latest Stroke news and research via News-Medical.Net
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
